ABOS Stock Analysis: Buy, Sell, or Hold?
ABOS - Acumen Pharmaceuticals, Inc. Common Stock
$2.20
0.07 (3.29%)
▲
5d:
-0.45%
30d:
-0.45%
90d:
-14.4%
BUY
MODERATE Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Aug 11, 2026
13d
Get Alerted When ABOS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABOS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ABOS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ABOS is currently trading at $2.20, which is considered oversold relative to its 30-day fair value range of $2.21 to $2.65.
Technical Outlook: Technically, ABOS is in a downtrend. Immediate support is located at $2.09, while resistance sits at $2.75. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.40 (+236.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABOS is in a downtrend. Immediate support is located at $2.09, while resistance sits at $2.75. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Implied Volatility is high (100th percentile), indicating expensive options premiums. This environment often favors selling options or covered calls to generate income. Wall Street analysts see significant upside, with an average price target of $7.40 (+236.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.21 -
$2.65
Company Quality Score
49/100
(HOLD)
Options IV Signal
100th percentile
(EVENT RISK)
Volume Confirmation
HIGH
Confidence Score
69.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Options expensive (IV 100th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 236.4% below Wall St target ($7.40)
Trading Range Analysis
30-Day Trading Range
$2.21 -
$2.65
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.78
(35.3%)
Support & Resistance Levels
Support Level
$2.09
Resistance Level
$2.75
Current Trend
Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.46
Wall Street Target
$7.40
(+236.4%)
Share & Embed Analysis
Last updated: July 28, 2026 8:15 AM ET
Data refreshes hourly during market hours. Next update: 9:15 AM
Data refreshes hourly during market hours. Next update: 9:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABOS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1079 | 58 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 54 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$48 | 54 HOLD |
